Detrás de los titulares sobre el cáncer

Estudio: El consumo frecuente de aspirina puede disminuir el riesgo de padecer cáncer de ovario

Aspirin may help lower the risk of ovarian cancer in people who have a high risk of the disease, according to a new analysis of 17 studies. While other preventive strategies have been found to more effectively lower the likelihood of developing ovarian cancer in high-risk women, taking aspirin daily or almost daily may reduce a person’s risk of developing ovarian cancer by 13 percent. The benefit was greater among people with additional risk factors for the disease. (Posted 2/22/23)

Este artículo está disponible en español.

Estudio: Trodelvy tiene resultados favorables en personas con cáncer de mama metastásico positivo al receptor hormonal

The study TROPiCS-2 showed that the drug Trodelvy (sacituzumab govitecan) improved progression-free survival when compared to chemotherapy in people with advanced metastatic ER/PR-positive, HER2-negative breast cancer who have few other treatment options. This drug does not yet have FDA approval for use in the hormone-positive setting. (Posted 1/18/23)

Update: On 02/03/2023 the FDA approved Trodelvy for patients with locally advanced or metastatic  breast cancer who have received hormonal therapy and at least two other types of treatment in the metastatic setting.

Este artículo está disponible en español.

Actualización: El estudio de la vacuna contra el cáncer de mama inicia con la participación de personas con mutaciones en los genes BRCA1 y PALB2

A new vaccine was first tested on people diagnosed with triple-negative breast cancer. The vaccine is now being tested to prevent breast cancer among people with an inherited mutation in BRCA1 or PALB2 who are at high risk and who are planning to have a risk-reducing mastectomy. (Posted 1/9/23) Este artículo está disponible en español.

Estudio: ¿Qué factores influyen en recibir una atención más agresiva en la etapa final de la vida para el cáncer de ovario?

Aggressive medical treatment is often given to people with terminal ovarian cancer when prior treatment has stopped working. This aggressive end-of-life treatment conflicts with clinical guidelines, may increase pain and suffering and does not extend life. This study found that the end-of-life care that a person with ovarian cancer receives is influenced by their doctors. (Posted 1/3/23)

Este artículo está disponible en español.

Estudio: Cáncer de mama en hombres: experiencias de pacientes y cirujanos

By surveying male breast cancer patients and the surgeons who treat them, researchers gained insight into the experiences of both groups, shedding light on an important issue for men with breast cancer. (Posted 12/22/22)

Este artículo está disponible en español.

Tema: Desigualdades por cáncer en las poblaciones indígenas estadounidenses y nativas de Alaska

The American Cancer Society released a special section in their 2022 Cancer Facts & Figures report that discussed cancer disparities in American Indian and Alaska Native populations in the United States. This review highlights the special section’s main points, including disparities in cancer screening, diagnosis and survival rates in native communities, as well as factors contributing to those disparities. (Posted 12/20/22)

Este artículo está disponible en español.

Directrices: Pautas sobre ejercicio, dieta y peso durante el tratamiento del cáncer

Most professional guidelines on exercise, diet and weight management have focused on the health of the general population and cancer survivors. The American Society of Clinical Oncology (ASCO) has now published evidence-based recommendations for exercise, diet and weight specifically for people who are in active treatment for cancer. (Posted 11/29/22)  Este artículo está disponible en español.

Estudio: Las biopsias líquidas ayudan a personalizar el tratamiento contra el cáncer de colon en etapa inicial

Liquid biopsies look for DNA or other products from cancer cells in the blood or other body fluids. These tests may be used to help find cancer recurrence early, monitor response to treatment or guide treatment selection for people diagnosed with cancer. This study looked at a type of liquid biopsy called “circulating tumor” (ctDNA) to identify people with early-stage colon cancer who can safely skip chemotherapy after surgery.  (Posted 11/22/22) Este artículo está disponible en español.

Estudio: Resultados prometedores, aunque prematuros, para personas con cáncer de recto con deficiencia de reparación de desajuste de ADN

A small research study tested the usefulness of the immunotherapy drug dostarlimab for treating locally advanced rectal cancer with a biomarker known as “dMMR” (DNA mismatch repair deficient). None of the participants had evidence of cancer six months later; some remained cancer free for up to 25 months). Many participants had Lynch syndrome. The remarkable response to this treatment may allow people with this particular subtype of rectal cancer to avoid potentially life-changing rectal surgery. (Posted 11/14/22) Este artículo está disponible en español.

Estudio: La prueba de detección de cáncer de próstata puede beneficiar a las personas con síndrome de Lynch

Initial results from the IMPACT trial show that PSA testing to screen for prostate cancer in people with Lynch syndrome can detect aggressive early prostate cancers. These findings support the use of PSA screening in men with Lynch syndrome, particularly men with an inherited mutation in an MSH2 or MSH6 gene. (Posted 11/10/22)

Este artículo está disponible en español.